著者
Eiko Saito Shiori Tanaka Sarah Krull Abe Mayo Hirayabashi Junko Ishihara Kota Katanoda Yingsong Lin Chisato Nagata Norie Sawada Ribeka Takachi Atsushi Goto Junko Tanaka Kayo Ueda Megumi Hori Tomohiro Matsuda Manami Inoue
出版者
National Center for Global Health and Medicine
雑誌
Global Health & Medicine (ISSN:24349186)
巻号頁・発行日
pp.2023.01001, (Released:2023-05-04)
参考文献数
34

Controlling avoidable causes of cancer may save cancer-related healthcare costs and indirect costs of premature deaths and productivity loss. This study aimed to estimate the economic burden of cancer attributable to major lifestyle and environmental risk factors in Japan in 2015. We evaluated the economic cost of cancer attributable to modifiable risk factors from a societal perspective. We obtained the direct medical costs for 2015 from the National Database of Health Insurance Claims and Specific Health Checkups of Japan, and estimated the indirect costs of premature mortality and of morbidity due to cancer using the relevant national surveys in Japan. Finally, we estimated the economic cost of cancer associated with lifestyle and environmental risk factors. The estimated cost of cancer attributable to lifestyle and environmental factors was 1,024,006 million Japanese yen (\) (8,460 million US dollars [$]) for both sexes, and \673,780 million ($5,566 million) in men and \350,226 million ($2,893 million) in women, using the average exchange rate in 2015 ($1 = \121.044). A total of \285,150 million ($2,356 million) was lost due to premature death in Japan in 2015. Indirect morbidity costs that could have been prevented were estimated to be \200,602 million ($1,657 million). Productivity loss was highest for stomach cancer in men (\28,735 million/$237 million) and cervical cancer in women (\24,448 million/$202 million). Preventing and controlling cancers caused by infections including Helicobacter pylori, human papillomavirus and tobacco smoking will not only be life-saving but may also be cost-saving in the long run.
著者
Kota Katanoda Megumi Hori Eiko Saito Akiko Shibata Yuri Ito Tetsuji Minami Sayaka Ikeda Tatsuya Suzuki Tomohiro Matsuda
出版者
Japan Epidemiological Association
雑誌
Journal of Epidemiology (ISSN:09175040)
巻号頁・発行日
vol.31, no.7, pp.426-450, 2021-07-05 (Released:2021-07-05)
参考文献数
91
被引用文献数
69

Background: Unlike many North American and European countries, Japan has observed a continuous increase in cancer incidence over the last few decades. We examined the most recent trends in population-based cancer incidence and mortality in Japan.Methods: National cancer mortality data between 1958 and 2018 were obtained from published vital statistics. Cancer incidence data between 1985 and 2015 were obtained from high-quality population-based cancer registries maintained by three prefectures (Yamagata, Fukui, and Nagasaki). Trends in age-standardized rates (ASR) were examined using Joinpoint regression analysis.Results: For males, all-cancer incidence increased between 1985 and 1996 (annual percent change [APC] +1.1%; 95% confidence interval [CI], 0.7–1.5%), increased again in 2000–2010 (+1.3%; 95% CI, 0.9–1.8%), and then decreased until 2015 (−1.4%; 95% CI, −2.5 to −0.3%). For females, all-cancer incidence increased until 2010 (+0.8%; 95% CI, 0.6–0.9% in 1985–2004 and +2.4%; 95% CI, 1.3–3.4% in 2004–2010), and stabilized thereafter until 2015. The post-2000 increase was mainly attributable to prostate in males and breast in females, which slowed or levelled during the first decade of the 2000s. After a sustained increase, all-cancer mortality for males decreased in 1996–2013 (−1.6%; 95% CI, −1.6 to −1.5%) and accelerated thereafter until 2018 (−2.5%; 95% CI, −2.9 to −2.0%). All-cancer mortality for females decreased intermittently throughout the observation period, with the most recent APC of −1.0% (95% CI, −1.1 to −0.9%) in 2003–2018. The recent decreases in mortality in both sexes, and in incidence in males, were mainly attributable to stomach, liver, and male lung cancers.Conclusion: The ASR of all-cancer incidence began decreasing significantly in males and levelled off in females in 2010.
著者
川上 永子 堀 芽実 濱元 一美 杉原 勝美 Eiko Kawakami Megumi Hori Kazumi Hamamoto Katsumi Sugihara
雑誌
四條畷学園大学リハビリテーション学部紀要 = Annual reports of Faculty of Rehabilitation, Shijonawate Gakuen University
巻号頁・発行日
vol.6, pp.37-41, 2010

著者は先行研究にて、歯磨きの専門家でない作業療法士が歯磨き訓練を実施する際の具体的な訓練方法を提案した. その方法は1.歯磨き訓練マニュアルによる個別指導、2.手鏡を用いた視覚的フィードバックによる個別指導の2点であった. 今回、もともと左利きで69歳時に左片麻痺、71歳時に右片麻痺を呈した症例を対象に歯磨き訓練を実施した. 症例は69歳時の左片麻痺発症時に右手への利き手交換にてADLは自立していたが、71歳時の発症にて右片麻痺の方が重度であったために、再度機能低下した左手でのADL獲得をもとめられている. 歯磨き訓練内容については前回の報告とほぼ同様の方法を用いた. ただし、実施期間は3ヶ月としOTRが直接指導するのは週5回とした. 判定は歯科衛生士によるO'Learyのプラークコントロールレコードにより口腔内の磨き残しを算出した. その結果、口腔内の磨き残しが顕著に減少し、口腔機能も改善したので考察を含め報告する.
著者
Setsuo Kinoshita Tadahaya Mizuno Megumi Hori Michiaki Kohno Hiroyuki Kusuhara
出版者
The Pharmaceutical Society of Japan
雑誌
Biological and Pharmaceutical Bulletin (ISSN:09186158)
巻号頁・発行日
vol.42, no.12, pp.2069-2075, 2019-12-01 (Released:2019-12-01)
参考文献数
18
被引用文献数
3

Proteome profiling based on two-dimensional (2D)-DIGE might be a useful tool for investigating drug-like compounds and the mode of action of drugs. However, obtaining data for profiling requires high labor costs, and it is difficult to control the reproducibility of spot positions because 2D-DIGE usually requires large-size glass plates and spot alignments are greatly affected by the quality of DryStrips and polyacrylamide gels (PAGs). Therefore, we have developed a novel platform by employing small size DryStrips and PAGs, and an image analysis strategy based on dual correction of spot alignment and volume. Our system can automatically detect a large number of consistent spots through all images. Cytosol fractions of HeLa cells treated with dimethyl sulfoxide (DMSO) or bortezomib were analyzed, 1697 consistent spots were detected, and 775 of them were significantly changed with the treatment. Deviations between different days and lot sets of DryStrips and PAGs were investigated by calculating the correlation coefficients. The mean values of the correlation between days and lot sets were 0.96 and 0.94, respectively. Clustering analysis of all the treatment data clearly separated the DMSO or bortezomib treated groups beyond day deviations. Thus, we have succeeded in developing an easy-to-handle 2D-DIGE system that can be a novel proteome profiling platform.